Bob J. Scholte

5.8k total citations · 1 hit paper
110 papers, 4.7k citations indexed

About

Bob J. Scholte is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Genetics. According to data from OpenAlex, Bob J. Scholte has authored 110 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Pulmonary and Respiratory Medicine, 25 papers in Molecular Biology and 15 papers in Genetics. Recurrent topics in Bob J. Scholte's work include Cystic Fibrosis Research Advances (58 papers), Neonatal Respiratory Health Research (45 papers) and RNA Interference and Gene Delivery (10 papers). Bob J. Scholte is often cited by papers focused on Cystic Fibrosis Research Advances (58 papers), Neonatal Respiratory Health Research (45 papers) and RNA Interference and Gene Delivery (10 papers). Bob J. Scholte collaborates with scholars based in Netherlands, United States and Germany. Bob J. Scholte's co-authors include Hugo R. de Jonge, Jan Bijman, Pim J. French, P.W. Postma, Martina Wilke, Hettie M. Janssens, Magnus Ingelman‐Sundberg, Hans Jörnvall, Inger Johansson and J. Hikke van Doorninck and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Bob J. Scholte

107 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A functional CFTR assay using primary cystic fibrosis intestinal organoids

2013 734 citations Hugo R. de Jonge, Hettie M. Janssens et al. profile →

Peers

Countries citing papers authored by Bob J. Scholte

Since Specialization

Citations

This map shows the geographic impact of Bob J. Scholte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bob J. Scholte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bob J. Scholte more than expected).

Fields of papers citing papers by Bob J. Scholte

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bob J. Scholte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bob J. Scholte. The network helps show where Bob J. Scholte may publish in the future.

Co-authorship network of co-authors of Bob J. Scholte

This figure shows the co-authorship network connecting the top 25 collaborators of Bob J. Scholte. A scholar is included among the top collaborators of Bob J. Scholte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bob J. Scholte. Bob J. Scholte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Key inflammatory markers in bronchoalveolar lavage predict bronchiectasis progression in young children with CF 2024 ·Journal of Cystic Fibrosis ·Hamed Horati, Camilla Margaroli, Joshua D. Chandler, Matthew B. Kilgore, (unknown), Eleni‐Rosalina Andrinopoulou, Limin Peng, Lokesh Guglani, Harm Tiddens, Daan Caudri, Bob J. Scholte, Rabindra Tirouvanziam, Hettie M. Janssens	5
2	Oxidative stress and abnormal bioactive lipids in early cystic fibrosis lung disease 2019 ·Journal of Cystic Fibrosis ·Bob J. Scholte, Hamed Horati, (unknown), Rob J. Vreeken, Luke W. Garratt, Harm A.W.M. Tiddens, Hettie M. Janssens, Stephen M. Stick	28
3	Myeloperoxidase oxidation of methionine associates with early cystic fibrosis lung disease 2018 ·European Respiratory Journal ·Joshua D. Chandler, Camilla Margaroli, Hamed Horati, Matthew B. Kilgore, (unknown), (unknown), (unknown), Limin Peng, Lokesh Guglani, Karan Uppal, Young‐Mi Go, Harm A.W.M. Tiddens, Bob J. Scholte, Rabindra Tirouvanziam, Dean P. Jones, Hettie M. Janssens	39
4	Elastase Exocytosis by Airway Neutrophils Is Associated with Early Lung Damage in Children with Cystic Fibrosis 2018 ·American Journal of Respiratory and Critical Care Medicine ·Camilla Margaroli, Luke W. Garratt, Hamed Horati, Susanne Dittrich, Tim Rosenow, Samuel Montgomery, Dario L. Frey, Milton R. Brown, Carsten Schultz, Lokesh Guglani, Anthony Kicic, Limin Peng, Bob J. Scholte, Marcus Mall, Hettie M. Janssens, Stephen M. Stick, Rabindra Tirouvanziam	69
5	Transfection by cationic gemini lipids and surfactants 2018 ·MedChemComm ·(unknown), (unknown), Stijn F. M. van Dongen, Roeland J. M. Nolte, Bob J. Scholte, Martin C. Feiters	38
6	Genetic Inhibition Of The Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated To F508del Cystic Fibrosis Mutation 2015 ·Scientific Reports ·Valeria Tomati, Elvira Sondo, Andrea Armirotti, Emanuela Caci, Emanuela Pesce, Monica Marini, Ambra Gianotti, Young Joo Jeon, Michele Cilli, Angela Pistorio, Luca Mastracci, Roberto Ravazzolo, Bob J. Scholte, Ze’ev A. Ronai, Luis J. V. Galietta, Nicoletta Pedemonte	41
7	Role of IL-1β in Experimental Cystic Fibrosis upon P. aeruginosa Infection 2014 ·PLoS ONE ·Jennifer Palomo, (unknown), (unknown), Louis Fauconnier, (unknown), Flora Reverchon, Marc Le Bert, Dieudonnée Togbe, Ruvalic M. Buijs‐Offerman, (unknown), Valérie Quesniaux, Bob J. Scholte, Bernhard Ryffel	22
8	Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator 2012 ·Autophagy ·Alessandro Luciani, Valeria Rachela Villella, Speranza Esposito, Manuela Gavina, Ilaria Russo, Marco Silano, Stefano Guido, Massimo Pettoello‐Mantovani, Rosa Carnuccio, Bob J. Scholte, Maria Antonietta De Matteis, Maria Chiara Maiuri, Valeria Raia, Alberto Luini, Guido Kroemer, Luigi Maiuri	73
9	Critical role of cytosolic phospholipase A2α in bronchial mucus hypersecretion in CFTR-deficient mice 2010 ·European Respiratory Journal ·Fariel Dif, Yongzhong Wu, Pierre‐Régis Burgel, Mario Ollero, D. Leduc, Jamil Aarbiou, Florence Borot, Ignacio García-Verdugo, Clémence Martin, Michel Chignard, Dominique Israël‐Biet, Yoshiaki Kita, Bob J. Scholte, Lhousseine Touqui	29
10	Azithromycin fails to reduce increased expression of neutrophil-related cytokines in primary-cultured epithelial cells from cystic fibrosis mice 2009 ·Journal of Cystic Fibrosis ·(unknown), François Huaux, (unknown), Patrick Lebecque, Étienne Marbaix, Dominique Lison, Bob J. Scholte, Pierre Wallemacq, Teresinha Leal	21
11	Gemini-Like Peptide-Based Amphiphiles for Application in Gene Transfection 2007 ·Human Gene Therapy ·(unknown), Stijn F. M. van Dongen, Jamil Aarbiou, (unknown), Bob J. Scholte, Martin C. Feiters, Roeland J. M. Nolte	1
12	University of Wisconsin solution enhances gene therapy vector delivery under hypo- and normo-thermic conditions. 2007 ·American Journal of Transplantation ·Scot D. Henry, Herold J. Metselaar, (unknown), Bob J. Scholte, (unknown), Hugo W. Tilanus, Luc J. W. van der Laan	1
13	What have we learned from mouse models for cystic fibrosis? 2007 ·Expert Review of Molecular Diagnostics ·(unknown), Bob J. Scholte, Deborah Penque	17
14	Azithromycin reduces spontaneous and induced inflammation in ΔF508 cystic fibrosis mice 2006 ·Respiratory Research ·Rachida Legssyer, François Huaux, Jean Lebacq, Monique Delos, Étienne Marbaix, Patrick Lebecque, Dominique Lison, Bob J. Scholte, Pierre Wallemacq, Teresinha Leal	86
15	Proteomic analysis of nasal cells from cystic fibrosis patients and non‐cystic fibrosis control individuals: Search for novel biomarkers of cystic fibrosis lung disease 2006 ·PROTEOMICS ·Mónica Roxo‐Rosa, Gonçalo da Costa, Theo M. Luider, Bob J. Scholte, Ana Varela Coelho, Margarida D. Amaral, Deborah Penque	67
16	Real-time RT-PCR quantitation of mCLCA1 and mCLCA2 reveals differentially regulated expression in pre- and postnatal murine tissues 2002 ·Histochemistry and Cell Biology ·(unknown), (unknown), Georg von Samson‐Himmelstjerna, Bob J. Scholte, Achim D. Gruber	26
17	Morphological changes in the vas deferens and expression of the cystic fibrosis transmembrane conductance regulator (CFTR) in control, ?F508 and knock-outCFTR mice during postnatal life 2000 ·Molecular Reproduction and Development ·(unknown), Bart Van der Schueren, (unknown), (unknown), Harry Cuppens, Bob J. Scholte, Jean‐Jacques Cassiman	31
18	A multi-domain protein for β1 integrin-targeted DNA delivery 2000 ·Gene Therapy ·Elisabetta Fortunati, Erich Ehlert, (unknown), Claire Wyman, Johannes A. Eble, Frank Grosveld, Bob J. Scholte	21
19	A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo. 1996 ·Journal of Clinical Investigation ·Pim J. French, J. Hikke van Doorninck, (unknown), Elly Verbeek, Nadia A. Ameen, Christopher R. Marino, Hugo R. de Jonge, Jan Bijman, Bob J. Scholte	128
20	Regulation of chloride transport in cultured normal and cystic fibrosis keratinocytes 1992 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·(unknown), J. L. M. Keulemans, A. T. Hoogeveen, Bob J. Scholte, Arie B. Vaandrager, A.W.M. van der Kamp, M. Sinaasappel, Alice G.M. Bot, Hugo R. de Jonge, Jan Bijman	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact